Employees: 1,905
Size Zhejiang Starry Pharmaceutical (603520.SS) is a China Health Care company (Medical Specialties) with a market value of $491M, the 3745th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.55 on 18 Nov 2026.
Performance Over six months the shares fell 44.3%, against -17.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 9.4% over the last twelve months (peer median +5.4%); the operating margin is 2.7% (peer median 3.3%).
Valuation It trades at 25.8× forward earnings against a peer median of 19.7× (3rd most expensive of 10).
Capital Return on invested capital runs 2.2 points below its cost of capital (6.1% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.61B | CN¥2.45B | CN¥2.33B | CN¥2.18B | CN¥2.12B |
| Revenue growth | — | +5% | +7% | +3% | — |
| Gross profit | CN¥660M | CN¥450M | CN¥385M | CN¥465M | CN¥449M |
| EBITDA | n/a | CN¥311M | CN¥277M | CN¥325M | CN¥307M |
| Net income | CN¥26.6M | CN¥10.2M | -CN¥49.1M | CN¥44.2M | -CN¥75.9M |
| Free cash flow | -CN¥93.3M | -CN¥266M | -CN¥287M | -CN¥220M | -CN¥550M |
| Capital expenditure | CN¥190M | CN¥269M | CN¥481M | CN¥266M | CN¥472M |
| Total debt | CN¥2.82B | CN¥2.97B | CN¥2.68B | CN¥3.19B | CN¥2.99B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603520.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -4.6% | 10th lowest of 21 |
| 6-month return | -44.3% | -17.0% | 2nd lowest of 21 |
| Distance from 52-week high | -47.5% | -41.7% | 8th lowest of 21 |
| Revenue growth (TTM) | +9.4% | +5.4% | 6th highest of 21 |
| Operating margin | 2.7% | 3.3% | 11th highest of 21 |
| Forward P/E | 25.8× | 19.7× | 3rd most expensive of 10 |
| ROIC minus cost of capital | -2.2 pp | -1.6 pp | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 11.9× | -5.9% | +7.7% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 24.5× | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | n/a | 10.9% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | n/a | 36.0% | -6.9% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | n/a | n/a | n/a |